Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07073261
Active, not recruiting Observational

Prospective Multiethnic Validation of the Behçet's Syndrome Overall Damage Index (BODI)

NCT07073261 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Cagliari
Phase
Observational
Started
2021-07-23
Last updated
2025-07-18

Condition(s) studied

Behçet's Syndrome (BS)

Study summary

PROBE is an observational multicenter cohort study, consisting of a cross-sectional and a 5-years prospective phase, designed to target the major study objectives, such as testing the comprehensiveness of the Behçet's syndrome Overall Damage Index (BODI) in a wide and ethnically heterogeneous cohort of Behçet's syndrome patients, and investigating how damage assessed by the BODI correlates with other major long-term disease outcomes (5-years mortality and hospitalization rates).

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of BS according to ICBD or ISG criteria. Exclusion Criteria: * Subjects unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow interval visits.

Primary outcome measure(s)

  • 5-years mortality rate — 5 years
    Correlation between the irreversible organ damage measured by the BEhçet's syndrome Overall Damage Index (BODI) and the 5-years mortality rate.
  • 5-years hospitalization rate — 5 years
    Correlation between the irreversible organ damage measured by the BEhçet's syndrome Overall Damage Index (BODI) and the 5-years hospitalization rate.

Trial sites (1)

FacilityCityRegionStatus
Rheumatology Unit, University and AOU of Cagliari Monserrato Cagliari

More University of Cagliari trials in Italy

PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study Recruiting
Comprehensive Approach to Reduce Elderly Functional Decline in Diabetes: the CARED Study Recruiting
Biomarkers for Diagnosis and Treatment Response in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) Recruiting
FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI). Recruiting
Assessment Metabolic Flexibility in Middle-aged Individuals: The Nutritional Impact of Cheese Consumption Recruiting

Other trials for the same condition

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) Enrolling by invitation
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07073261 on ClinicalTrials.gov ↗ ← All trials in Italy